Skip to main content
Iranian Journal of Microbiology logoLink to Iranian Journal of Microbiology
. 2023 Apr;15(2):318–324. doi: 10.18502/ijm.v15i2.12484

Identification and pattern of antifungal susceptibility of Candida species isolated from cases of vaginitis in a tertiary care hospital in India

Gulnaz Bashir 1, Insha Altaf 1, Rabia Khurshid 2, Tufail Ahmed 1,*, Aamir Ali 1, Sofia Zaffar 1
PMCID: PMC10183080  PMID: 37193233

Abstract

Background and Objectives:

Vulvovaginal candidiasis (VVC) is one of the most frequent reasons for gynecological consultations. Candida albicans is responsible in the majority of cases. Lately, VVC caused by non-albicans Candida spp. (NAC), which are resistant to routinely used antifungals, is on the rise. This study was designed to determine the prevalence of Candida in patients suffering from vaginitis and to assess the predisposing factors along with identification of Candida species and evaluation of their susceptibility profile.

Materials and Methods:

High vaginal swabs were collected from 225 women. Sample processing consisted of Gram stain and culture onto Sabouraud’s dextrose agar and HiChrom Candida Differential agar. Isolates were identified and speciated using VITEK2 Compact System. Susceptibility testing was done using VITEK2 AST-Y S08 cards and disc diffusion.

Results:

Candida spp. were isolated from 94 (41.8%) of the cases. C. albicans was the predominant species (71.6%) followed by other NAC spp. (28.4%). Pregnancy and diabetes were the most frequently implicated risk factors (67.1% and 44.4%). High resistance was observed in NAC spp. as opposed to C. albicans to all antifungal agents tested.

Conclusion:

Empirical therapy with routinely used antifungals can be initiated for C. albicans. In the case of NAC spp., identification should be followed by susceptibility testing.

Keywords: Candidiasis, Vaginitis, Resistance, Antifungals, Reproductive health

INTRODUCTION

The inflammation of the vulvovaginal area with the established presence of Candida spp. by culture and in the absence of other infectious agents is referred to as vulvovaginal candidiasis (VVC). The patients present with symptoms of vulval pruritus, erythema, curd-like discharge, and a grey-white pseudo membrane (1). VVC accounts for a majority of gynecology consultations on an outpatient basis and affects more than two-thirds of women at least once during their lifetime (2, 3). The disease, though rarely lethal, is responsible for a high magnitude of morbidity around the world (4). Although Candida albicans (C. albicans) is isolated from a majority of the cases, lately, increased isolation of non-albicans Candida (NAC) spp. which have reduced susceptibility to routinely used antifungals has complicated the situation (5). This increase in resistant species can be attributed to the indiscriminate use of over-the-counter anti-fungal agents, leading to severe financial implications due to treatment failure in such cases (6).

The rise in the frequency of VVC caused by NAC spp. with an increase in resistance to routinely used antifungals has led to protocols being developed for prompt identification and in-vitro antifungal susceptibility testing. Given the lack of data in this region regarding VVC, this study was undertaken to identify the Candida species causing VVC and study their antifungal susceptibility profile.

MATERIALS AND METHODS

This was a cross-sectional, hospital-based study conducted in the Department of Microbiology, in collaboration with the Department of Gynecology and Obstetrics of an apex tertiary care hospital for a period of 18 months (November 2017 to May 2019). Before starting the study, approval was sought from the Institutional Ethics Committee.

Patient and samples

Women over 18 years of age who presented with self-reported symptoms of vaginal infection and were labelled as vaginitis on examination by the attending gynecologist were included in the study. Patients already on antifungals, who refused to participate and those already recruited in the study were excluded. Simultaneously, samples from 100 women attending the gynecology clinic for unrelated causes, who mandated a vaginal examination were taken and comprised the control group for the study. Informed consent was taken at the time of inclusion in the study from the cases and the controls along with a standard proforma used to document socio-demographic and clinical information.

Specimen collection

Upon admission, the attending gynecologist performed a detailed clinical examination and recorded the signs of vaginal infection. A sterile vaginal speculum was inserted to examine and appreciate the state of the cervix. Two high vaginal swabs (HVS) were collected aseptically, labelled and transported. A total of 225 patients were enrolled in the study.

Processing of samples

One swab was used for the preparation of a Gram smear which was used to document the presence of yeast cells as depicted in Fig. 1. The second swab was inoculated onto freshly prepared Sabouraud’s dextrose agar (SDA) with chloramphenicol (HiMedia Laboratories Pvt. Ltd, India) and HiCrome Candida Differential Agar (HCDA) (HiMedia Laboratories Pvt. Ltd, India). SDA tubes were examined for growth after 24–48 hours of incubation. Candida colonies appear opaque white to creamy on SDA. HCDA is a chromogenic differential media recommended for the rapid isolation and characterization of Candida species from mixed cultures as illustrated in Fig. 2. The plates were examined for growth and color after 24–48 hours of incubation. Further processing was done using the growth on HCDA.

Fig. 1.

Fig. 1.

Photomicrograph of a Gram smear of HVS showing Candida cells with pseudohyphae and epithelial cells (1000x).

Fig. 2.

Fig. 2.

Candida colonies on HiCrome Candida Differential Agar showing various pigmentations.

Candida species were identified using the VITEK2 Compact system (bioMérieux) (software version 8.01). Briefly, a standardized inoculum suspension (1.8 to 2.0 McFarland) was placed into a sterile polystyrene test tube along with a VITEK2 cassette for each isolate. The loaded cassettes were placed inside the VITEK2 instrument. The card consists of colorimetric reagents that are incubated and interpreted automatically. The reagent cards have 64 wells that contain an individual test substrate which measures various metabolic activities. An optically clear film present on both sides of the card allows for the appropriate level of oxygen transmission while maintaining a sealed vessel. The time of incubation varied from 9.1 to 27.1 hours (7).

Antifungal sensitivity was done by VITEK2 AST YS08 card which gave susceptibility to fluconazole (FLC), voriconazole (VRC), amphotericin B (AP), caspofungin (CAS), micafungin (MYC), and flucytosine (FLU) and disc diffusion method for itraconazole (ITR), ketoconazole (KET), and clotrimazole (CLO) (HiMedia Laboratories Pvt. Ltd, India). The disc diffusion method was done as per the CLSI guidelines (8). Mueller Hinton Agar with 2% glucose and methylene blue was inoculated with a 0.5 McFarland suspension of the growth for performing disc diffusion. A lawn culture was made on the agar with discs containing antifungal agents (CLO-10mcg, KET-10mcg, and ITR-10mcg) applied to the surface of the inoculated agar and pressed to ensure optimal contact. Plates were inverted and incubation was done at 37°C. After incubating for 24 hours, the plates were examined and the zones of inhibition surrounding the discs were measured and compared with established zone size ranges as depicted in Table 1 to determine the sensitivity.

Table 1.

The interpretative criteria as per the manufacturer’s guidelines (HiMedia)

Antifungal Agent (HiMedia) Disk Content Zone Diameter, Nearest Whole (mm)*

S S-DD R NS
Ketoconazole 10 μg >30 23–29 <22 -
Itraconazole 10 μg >15 10–14 <9 -
Clotrimazole 10 μg >20 12–19 <11 -
*

Susceptible (S), susceptible-dose dependent (S-DD), resistant (R), and non-susceptible (NS) interpretive categories are defined in Section 8.2 of CLSI document M44-A2 (8).

Statistical analysis

All the categorical variables have been shown in terms of frequency and percentage. Sensitivity and predictive values were calculated using standard statistical tests (Chi-square test). Results have been discussed on a 5% level of significance. p-value <0.05 was considered significant while p < 0.01 was considered highly significant. The analysis was done with the help of statistical software, SPSS version 22 (9).

RESULTS

A total of 225 patients who were clinically diagnosed with vaginitis and 100 controls were included in this study. The controls were selected by simple random sampling. Among the study population, a total of 153 (68%) patients attended the outpatient department whereas 72 (32%) were sampled from the inpatient department. The control group was taken from those patients attending the outpatient department. The age distribution of the study population is depicted in Fig. 3. The risk factors and symptoms are depicted in Tables 2 and 3.

Fig. 3.

Fig. 3.

Age-wise distribution of cases

Table 2.

Risk factors present in the studied population

Risk factors Total Positive for VVC p-value

N %
Married 159 78 49 0.001*
Pregnant 151 74 49 0.002*
Diabetes 100 65 65 0.000*
Antibiotic Usage 39 20 51.2 0.213
Menopause 6 2 33.3 0.574
OCP 3 2 66.6 0.573
Immunosuppressive state 1 1 100 0.418

OCP-Oral contraceptive pills

*

Statistically significant

Table 3.

Clinical presentation of the studied population

Clinical features Total Positive for VVC p-value

N %
Pruritus+Erythema+Discharge 20 19 95 0.000*
Pruritus + Discharge 43 42 97.6 0.000*
Discharge + Erythema 44 38 86.3 0.000*
Pruritus + Erythema 46 21 45.6 0.616
Erythema 102 42 41.1 0.893
Discharge 107 82 76.6 0.000*
Pruritus 129 52 40.3 0.682
*

Statistically significant

Of 225 cases, 94 (41.8%) were positive for Candida spp. on culture while only 16 (16%) of the controls were positive for Candida spp. on culture as depicted in Table 4. Of the 94 cases that had a positive culture on the primary selective media, only 57 (60%) had a positive Gram smear. A total of 102 Candida isolates were recovered from 94 patients. C. albicans was the most common species both in the controls (100%) as well as the cases (71.6%). The remaining 28.4% of the cases were due to the NAC spp. and consisted of 4 different species. C. glabrata (n=16, 15.7%) was the most commonly isolated NAC spp. followed by C. kefyr (n=7, 6.9%), C. krusei (n=5,4.9%), and C. parapsilosis (n=1,1%) as illustrated in Fig. 4.

Table 4.

Isolation of Candida spp. amongst cases and controls

Subjects Total Positive for Candida spp. p-value
Cases 225 94 (41.8%) 0.0028*
Controls 100 16 (16%)

Fig. 4.

Fig. 4.

Candida spp. isolated from cases of VVC

In contrast to the five different spp. causing candidiasis in the cases, only one Candida spp. was found in the controls (C. albicans). Mixed infection with two species of Candida was seen in 8 (8.5%) cases while the remaining patients (n=86, 91.5%) had only one Candida spp. isolated.

Antifungal susceptibility was done for all isolates recovered during the study period. In general, higher rates of resistance for all antifungals were observed in NAC spp. as opposed to C. albicans as depicted in Table 5.

Table 5.

Antifungal susceptibility profile of Candida spp. recovered from the study population

Organism n (%) Fluconazole* Voriconazole* Amphotericin B*



S SDD R S SDD R S SDD R
C. albicans 72 (98.6) 0 1 (1.4) 73 (100) 0 0 73 (100) 0 0
NAC 11 (37.9) 13 (44.8) 5 (17.2) 29 (100) 0 0 29 (100) 0 0
All Isolates 83 (81.4) 13 (12.7) 6 (5.9) 102 (100) 0 0 102 (100) 0 0
Caspofungin* Micafungin* Flucytosine*



S SDD R S SDD R S SDD R
C. albicans 73 (100) 0 0 72 (98.6) 0 1 (1.4) 73 (100) 0 0
NAC 13 (44.8) 15 (51.7) 1 (3.4) 27 (93.1) 0 2 (6.9) 24 (82.8) 0 5 (17.2)
All Isolates 86 (84.3) 15 (14.7) 1 (1) 99 (97.1) 0 3 (2.9) 97 (95.1) 0 5 (4.9)
Itraconazole# Ketoconazole# Clotrimazole#



S SDD R S SDD R S SDD R
C. albicans 66 (90.4) 5 (6.8) 2 (2.7) 20 (27.4) 30 (41.1) 23 (31.5) 58 (79.5) 10 (13.7) 5 (6.8)
NAC 24 (82.8) 4 (13.8) 1 (3.4) 6 (20.7) 10 (34.5) 13 (44.8) 17 (58.6) 7 (24.1) 5 (17.2)
All Isolates 90 (88.2) 9 (8.8) 3 (2.9) 26 (25.5) 40 (39.2) 36 (35.3) 75 (73.5) 17 (16.7) 10 (9.8)
*

AST done by VITEK2

#

AST done by Disc Diffusion

DISCUSSION

Despite having a worldwide distribution, the frequency of VVC is greatly affected by local and regional socioeconomic factors (10). As such, updated epidemiological data from different areas is an important tool for health service planning. The present study was carried out to find out the epidemiology of VVC in the region, and identify the various Candida spp. involved along with antifungal susceptibility testing of the isolates.

The prevalence of Candida spp. in the patients who were recruited in the study was 41.8% (n=94) whereas, amongst the controls, it was 16% (n=16) (p-value < 0.01). As the controls were recruited based on the absence of symptoms of vaginitis, it can be safely assumed that the isolation of Candida in this subset suggested colonization rather than true infection. Studies done elsewhere have reported different rates of infection (6, 1113). Multiple factors like geographical location, socioeconomic status of patients, underlying factors and methods of testing can affect the prevalence rates between studies.

Patient age ranged from 18–50 years (median=29 years). The majority of the patients were in the age group of 26–30 years (31.1%) followed by 31–35 years (28.9%) and 21–25 years (22.6%). Similar results were reported elsewhere (6, 1113). The high incidence of VVC in this age group has been attributed to lower levels of protective cervical antibodies, increased sexual activity, and the influence of reproductive hormones (14).

Amongst the patients enrolled, 159 (70.6%) were married with 151 (67.1%) being pregnant. Amongst the pregnant females, the highest percentage of the patients was in the third trimester (n=117, 77.5%), followed by the second trimester (n=20, 13.2%) and first trimester (n=14, 9.2%) Similar findings were observed in other studies where the incidence of VVC increases with gestational age and is highest in the third trimester (15, 16).

The most prominent risk factor for VVC in the study was found to be marriage (n=159, 70.6%) followed by pregnancy (n=151, 67.1%) and diabetes (n=100, 44.4%) with a significant association (p-value < 0.01). Several patients had multiple risk factors. Our results were in agreement with other studies (17, 18). It has been well documented that Candida spp. require a carbon source for growth and pregnancy provides the ideal environment due to a high level of reproductive hormones which induce an increase in glycogen content in the vaginal epithelial cells (10). Some studies have also reported that estrogen has a direct effect on the growth of Candida and its adherence to the vaginal epithelium (19).

The most prominent presenting symptom among the study population was pruritus (n=129, 57.3%) followed by discharge (n=107, 47.5%) and erythema (n=102, 45.3%). Many patients presented with multiple symptoms. In the study, VVC was commonly associated with thick, white curd-like discharge and its association was significant (p-value <0.01).

Several identification systems have been developed and are commercially available. However, microscopy remains valuable as a quick and inexpensive method of identification, although it lacks sensitivity. Direct microscopic examinations of the Gram-stained smear of HVS revealed budding yeast cells only in 57 (25.3%) of cases and all of these cases yielded Candida spp. on culture. Among the culture-positive cases, the sensitivity of the Gram smear was 60%. Therefore, as previously reported, a negative smear result does not rule out the presence of disease. It reemphasizes the fact that culture is more sensitive than microscopy and should be preferred over microscopy as has been advocated by other authors (20).

A total of 102 Candida isolates were recovered from 94 patients. Mixed infection with two species of Candida was seen in 8 (3.57%) cases while the remaining 94 (96.5%) had a single spp. isolated. C. albicans was the most common species in cases (n=73, 71.6%) as well as controls (n=16, 100%). The remaining 29 (28.4%) cases were due to the NAC spp. and consisted of 4 different species.

Though C. albicans (71.6%) remained the predominant species isolated in the present study, NAC spp. were isolated in considerable proportions (28.4%). Furthermore, in accordance with some studies, C. glabrata (15.7%) was the commonest NAC spp. isolated (18, 21). With higher resistance levels in NAC spp. to the commonly prescribed azole-based treatments, the consequences for women affected by these strains might be incapacitating. Therefore, identification up to the species level should be routinely done for Candida infections to ensure targeted therapy. A striking observation in this study is that NAC spp., although low in number, still accounts for a considerable proportion of the cases in VVC (n=29, 28.4%). The high isolation of NAC spp. in this hospital-based study may be because complicated, chronic, and unresponsive cases of VVC are usually referred to this center.

Antifungal susceptibility testing for VVC was rarely indicated in the past given the limited reports of VVC caused by resistant C. albicans strains, and low prevalence rates of NAC spp. (22). In the present study a substantial number of NAC spp. (28.4%) were isolated from cases of VVC. The antifungal susceptibility depicted in Table 5 shows the highest overall resistance to KET (35.3%), followed by CLO (9.8%) and FLC (5.9%). NAC spp. in the study showed higher resistance rates as compared to C. albicans. Similar results have been reported elsewhere (18, 21). Worth mentioning is that although all isolates of C. albicans in the study were sensitive to most of the antifungals, one isolate was found to be resistant to FLC.

An increase in NAC infections and the emergence of azole-resistant C. albicans in VVC cases was seen in this study. Resistance to commonly used antifungal agents among NAC spp. makes it imperative that species identification be carried out in routine laboratories for the initiation of appropriate antifungal therapy. Also, surveillance of susceptibility profiles ensures that the empiric treatment regimens are validated regularly.

CONCLUSION

Vulvovaginal candidiasis cannot be diagnosed by clinical criteria alone. Culture is valuable for identifying the species of Candida and performing antifungal susceptibility, especially in pregnant and/or diabetic patients who present with discharge. This helps in the avoidance of empirical therapy which can prevent the emergence of resistance to antifungal agents. C. albicans was the most commonly isolated species, the majority of the strains being sensitive to all the antifungals tested. Empirical therapy with routinely used antifungals can be initiated for this species without the need for drug susceptibility testing in our setting. In the case of NAC spp., identification should be followed by susceptibility testing as the majority of the NAC spp. were found to be resistant to commonly used antifungal agents. The emergence of resistant NAC spp. can lead to treatment failures leading to recurrent VVC.

The study could not find a statistically significant influence between the use of broad-spectrum antibiotics, oral contraceptive pills and immunosuppressive states with the incidence of VVC. The reason could be the smaller number of patients with these predisposing factors. Further studies need to be done to find out a correlation between them. Also, yeast could not be identified as the causative agent in the majority of the symptomatic women. This finding requires due consideration and indicates the need to look for other etiological agents causing vaginitis.

REFERENCES

  • 1.Loveless M, Myint O. Vulvovaginitis-presentation of more common problems in pediatric and adolescent gynecology. Best Pract Res Clin Obstet Gynaecol 2018; 48: 14–27. [DOI] [PubMed] [Google Scholar]
  • 2.Del-Cura González I, García-de-Blas González F, Cuesta TS, Martín Fernández J, Del-Alamo Rodríguez JM, Escriva Ferrairo RA, et al. Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care. BMC Public Health 2011; 11: 63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J (Engl) 2016; 129: 1161–1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fidel PL., Jr. History and new insights into host defense against vaginal candidiasis. Trends Microbiol 2004; 12: 220–227. [DOI] [PubMed] [Google Scholar]
  • 5.Gross NT, Arias ML, Moraga M, Baddasarow Y, Jarstrand C. Species distribution and susceptibility to azoles of vaginal yeasts isolated prostitutes. Infect Dis Obstet Gynecol 2007; 2007: 82412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kalaiarasan K, Singh R, Chaturvedula L. Fungal profile of vulvovaginal Candidiasis in a tertiary care hospital. J Clin Diagn Res 2017; 11: DC06–DC09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ligozzi M, Bernini C, Bonora MG, De Fatima M, Zuliani J, Fontana R. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. J Clin Microbiol 2002; 40: 1681–1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.M44-A2 Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline—Second Edition (2009). www.clsi.org
  • 9.Aniebue UU, Nwankwo TO, Nwafor MI. Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. Niger J Clin Pract 2018; 21: 1017–1022 [DOI] [PubMed] [Google Scholar]
  • 10.Disha T, Haque F. Prevalence and risk factors of vulvo-vaginal Candidosis during pregnancy: A review. Infect Dis Obstet Gynecol 2022; 2022: 6195712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu J, Zeng M, Yang L, Mao Y, He Y, Li M, et al. Prevalence of reproductive tract infections among women preparing to conceive in Chongqing, China: trends and risk factors. Reprod Health 2022; 19: 197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009; 144: 68–71. [DOI] [PubMed] [Google Scholar]
  • 13.Ragunathan L, Poongothai GK, Sinazer AR, Kannaiyan K, Gurumurthy H, Jaget N, et al. Phenotypic characterization and antifungal susceptibility pattern to fluconazole in Candida species isolated from vulvovaginal Candidiasis in a tertiary care hospital. J Clin Diagn Res 2014; 8: DC01–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Disha T, Haque F. Prevalence and risk factors of vulvovaginal Candidosis during pregnancy: A Review. Infect Dis Obstet Gynecol 2022; 2022: 6195712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mulinganya G, De Vulder A, Bisimwa G, Boelens J, Claeys G, De Keyser K, et al. Prevalence, risk factors and adverse pregnancy outcomes of second trimester bacterial vaginosis among pregnant women in Bukavu, Democratic Republic of the Congo. PLoS One 2021; 16(10): e0257939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wang W, Hao J, An R. Abnormal vaginal flora correlates with pregnancy outcomes: A retrospective study from 737 pregnant women. Eur J Obstet Gynecol Reprod Biol 2022; 272: 64–68. [DOI] [PubMed] [Google Scholar]
  • 17.Gunther LSA, Martins HPR, Gimenes F, de Abreu ALP, Consolaro MEL, Svidzinski TIE. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. Sao Paulo Med J 2014; 132: 116–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Masri SN, Noor SM, Nor LA, Osman M, Rahman MM. Candida isolates from pregnant women and their antifungal susceptibility in a Malaysian tertiary-care hospital. Pak J Med Sci 2015; 31: 658–661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Aguin TJ, Sobel JD. Vulvovaginal candidiasis in pregnancy. Curr Infect Dis Rep 2015; 17: 462. [DOI] [PubMed] [Google Scholar]
  • 20.Marot-Leblond A, Nail-Billaud S, Pilon F, Beucher B, Poulain D, Robert R. Efficient diagnosis of vulvovaginal Candidiasis by use of a new rapid immunochromatography test. J Clin Microbiol 2009; 47: 3821–3825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mutua F, Revathi G, Machoki JM. Species distribution and antifungal sensitivity patterns of vaginal yeasts. East Afr Med J 2010; 87: 156–162. [DOI] [PubMed] [Google Scholar]
  • 22.Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008; 22: 637–652. [DOI] [PubMed] [Google Scholar]

Articles from Iranian Journal of Microbiology are provided here courtesy of Tehran University of Medical Sciences

RESOURCES